Publications

Chapters, Manuals, and Guidelines

• Pink Book’s Chapter on Meningococcal Disease
  Epidemiology and Prevention of Vaccine-Preventable Diseases
• Travelers’ Health: Yellow Book – Chapter on Meningococcal Disease
  CDC’s Health Information for International Travel (Prevention of Specific Infectious Diseases)
• Surveillance Manual’s Chapter on Meningococcal Disease
  Manual for the Surveillance of Vaccine-Preventable Diseases

Vaccine Recommendations and Licensures

View all current and historical meningococcal vaccine recommendations from the Advisory Committee for Immunization Practices. Current recommendations are also listed below:

• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — Advisory Committee on Immunization Practices, 2016. MMWR. 2017;66(19):509–13.
• MacNeil JR, Rubin L, Patton M, et al. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons – Advisory Committee on Immunization Practices, 2016. MMWR. 2016;65(43):1189-94.
• MacNeil JR, Rubin L, Folaranmi T, et al. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(4):1171-6.
• Folaranmi T, Rubin L, Martin, SW, Patel M, MacNeil JR. Use of Serogroup B Meningococcal Vaccines in Persons Ages ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(22):608-12.
• Use of MenACWY-CRM Vaccine in Children Aged 2 through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR. 2014;63(24):527-30.
• Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR02):1-22.

Top of Page

Surveillance, Epidemiology, and Outbreaks

• McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil J. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–7.
• Cohn AC, MacNeil J, Harrison LH, et al. Effectiveness and Duration of Protection of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine. Pediatrics. 2017;139(2).
• Bazan JA, Peterson AS, Kirkcaldy RD, et al. Notes from the Field. Increase in Neisseria meningitidis-associated Urethritis among Men — Ohio and Michigan, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:550–2.
• Blain A, Mandal S, Wu H, et al. Penicillin Use in Meningococcal Disease Management, Active Bacterial Core Surveillance (ABCs) Sites, 2009. Open Forum Infect Dis. 2016 Jul. 3(3): doi: 10.1093/ofid/ofw152
• Harris CM, Wu HM, Hall HI, et al. Meningococcal Disease in Patients with Human Immunodeficiency Virus Infection: A Review of Cases Reported through Active Surveillance in the United States, 2000–2008. Open Forum Infect Dis. 2016 Dec 20;ofw226. doi: 10.1093/ofid/ofw226.
• Sidikou F, Zaneidou M, Alkassoum I, et. al. Emergence of Epidemic Neisseria meningitidis Serogroup C in Niger, 2015: An Analysis of National Surveillance Data. Lancet Infect Dis. 2016;16(11):1288–94.
• Rondy M, Issifou D, Alkassoum IS, et al. Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis — Niamey, Niger, June 2015. PLoS Currents. 2016 Apr 18. Edition 1.
• Kambiré D, Soeters HM, Ouédraogo-Traoré R, et al. Nationwide Trends in Pneumococcal Meningitis Before the Introduction of 13-valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013. PLoS One. 2016;11(11):e0166384.
• Nanduri S, Foo C, Ngo V, et al. Outbreak of serogroup C meningococcal disease primarily affecting men who have sex with men — Southern California, 2016. MMWR. 2016;65:1–3.
• Breakwell L, Vogt TM, Fleming D, et al.. Understanding factors affecting university A students’ decision to receive an unlicensed serogroup B meningococcal vaccine. J Adolesc Health. Epub ahead of print. Aug 2016.
• Kamiya H, MacNeil JR, Blain A, et al. Notes from the Field: Meningococcal Disease among Men Who Have Sex with Men — United States, January 2012–June 2015. MMWR. 2015;64(44):1256–7.
• Cohn A, MacNeil J. The Changing Epidemiology of Meningococcal Disease. Infect Dis Clin North Am. 2015;29(4):667–77.
• Djingarey MH, Diomandé FV, Barry R, et al. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014. Clin Infect Dis. 2015;61(Suppl 5):S434–41.
• Diomandé FV, Djingarey MH, Daugla DM, et al. Public Health Impact After the Introduction of PsA-TT: The First 4 Years. Clin Infect Dis. 2015;61(Suppl 5):S467–72.
• Diomandé FV, Yameogo TM, Vannice KS, et al. Lessons Learned from Enhancing Vaccine Pharmacovigilance Activities during PsA-TT Introduction in African Countries, 2010–2013. Clin Infect Dis. 2015;61(Suppl 5):S459–66.
• McNamara LA, Shumate, AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccines in the US in response to a university outbreak. Pediatrics. 2015;135(5):798-804.
• Meyer SA, Kambou JL, Cohn A, et al. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso – Implications for introduction of PsA-TT into the Expanded Programme on Immunization. Vaccine. 2015;33(12):1492-8.
• MacNeil JR, Bennett N, Farley MM, et al. Epidemiology of infant meningococcal disease in the United States, 2006–2012. Pediatrics. 2015;153(2):e305-11.
• Patel M, Romero-Steiner S, Broderick MP, et al. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel. Vaccine. 2014; 32(30):394-9.
• MacNeil JR, Medah I, Koussoubé D, et al. Neisseria meningitis serogroup W, Burkina Faso, 2012. Emerg Infect Dis. 2014;20(3):394-9.
• Wiringa AE, Shutt KA, Marsh JW, et al. Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005. PLos One. 2013;8(12):e82048.
• Tartof S, Cohn A, Tarbagndo F, et al. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One. 2013: 8(5):e63605.
• Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344-8.
• Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354-63.
• Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs. 2013;73:1147-55.
• Terranella A, Beekmann SE, Polgreen PM, Cohn A, Wu HM, Clark TA. Practice patterns of infectious disease physicians for management of meningococcal disease. Pediatr Infect Dis J. 2012;31:e208–12.
• Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 2012;30 Suppl 2:B40–5.
• Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307:614–5.
• Terranella A, Cohn A, Clark T. Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist. 2011;4:161-9.
• MacNeil JR, Thomas JD, Cohn AC. Meningococcal disease: shifting epidemiology and genetic mechanisms that may contribute to serogroup C virulence. Curr Infect Dis Rep. 2011;13:374-9.
• MacNeil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451-5.
• Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364:2016-25.
• Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-91.
• Cohen C, Singh E, Wu HM, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa.. AIDS. 2010;24(9):1351-60.
• Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of Ciprofloxacin-Resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92.
• Weiss D, Stern EJ, Zimmerman C, et al. Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clin Infect Dis. 2009;48:894-901.
• CDC. Emergence of -resistant Neisseria meningitidis-Minnesota and North Dakota, 2007-2008. MMWR. 2008;57(07):173-175.
• Dull P, Abdelwahab J, Sacchi C, et al. Neisseria meningitidis Serogroup W-135 Carriage among US Travelers to the 2001 Hajj. J Infect Dis. 2005;191:33-9.
• Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant Meningococcal Disease. Emerg Infect Dis. 2005;11(6):977-9.
• Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States. Pediatrics. 2005;115(5):1220-32.
• McEllistrem MC, Kolano JA, Pass MA, et al. Correlating Epidemiologic Trends with the Genotypes Causing Meningococcal Disease, Maryland. Emerg Infect Dis. 2004;10(3):451-6.
• Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect Dis J. 2003;22:418-22.
• Kellerman S, McCombs K, Ray M, et al. Genotype-Specific Carriage of Neisseria meningitidis in Georgia Counties with Hyper- and Hyposporadic Rates of Meningococcal Disease. J Infect Dis. 2002;186:40-8.
• Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J. Meningococcal Disease. NEJM. 2001; 344:1378-1388.
• Sacchi C, Whitney A, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis. 2000; 182:1169-1176.
• CDC. Serogroup W-135 Meningococcal Disease Among Travelers Returning From Saudi Arabia – United States, 2000. MMWR. 2000;49(16):345-6.
• CDC. Meningococcal Disease – New England, 1993 – 1998. MMWR. 1999;48(29):629-633.
• Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux J. Epidemiology of bacterial meningococcal in Niamey, Niger, 1981-1996. Bull World Health Organ. 1999; 77: 499-508.
• CDC. Control and Prevention of Meningococcal Disease and Control and Prevention of Serogroup C Meningococcal Disease: Evaluation and Management of Suspected Outbreaks. MMWR. 1997;46(RR-5):1-51.
• CDC. Serogroup Y Meningococcal Disease – Illinois, Connecticut, and Selected Areas, United States, 1989-1996. MMWR. 1996;45(46):1010-4.
• CDC. Serogroup B Meningococcal Disease – Oregon, 1994. MMWR. 1995;44(07):121-124.

Top of Page

Laboratory

• Kretz CB, Retchless AC, Sidikou F, et al. Whole-genome characterization of epidemic Neisseria meningitidis serogroup C and resurging serogroup W, Niger, 2015. Emerg Infect Dis. 2016. 22(10):1762–8.
• Retchless AC, Hu F, Ouedraogo AS, et al. The establishment and diversification of epidemic-associated serogroup W meningococcus in the African meningitis belt, 1994–2012. mSphere. 2016;1(6):1–11.
• Wang X, Schutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis. 2015;211(12):1887–94.
• Collard JM, Wang X, Mahamane AE, et al. A five-year field assessment of rapid diagnostic tests for meningococcal meningitis in Niger by using the combination of conventional and real-time PCR assays as a gold standard. Trans R Soc Trop Med Hyg. 2014;108(1):6-12.
• Hoiseth SK, Murphy E, Andrew L, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor-H binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J. 2013;32(10):1096-101.
• Wu HM, Cordeiro SM, Harcourt BH, et al. Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis. BMC Infect Dis. 2013;22:13:26.
• Rishishwar L, Katz LS, Sharma NV, et al. Genomic basis of a polyagglutinating isolate of Neisseria meningitidis. J Bacteriol. 2012;194:5649–56.
• Thomas J, Hatcher CP, Satterfield DA, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361.
• Dolan Thomas J, Hatcher CP, Satterfield DA, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361.
• Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a vivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum Vaccin. 2011;7:68-74.
• Katz LS, Humphrey JC, Conley AB, et al. Neisseria Base: a comparative genomics database for Neisseria meningitidis. Database. Epub ahead of print. Sept 2011.
• Marsh JW, Shutt KA, Pajon R, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine. 2011;29:6049-58.
• Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29:4739-44.
• Harrison LH, Shutt KA, Schmink S, et al. Population structure of Invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era, United States, 2000-2005. J Infect Dis. 2010;201:1208-24.
• Kislyuk AO, Katz LS, Agrawal S, et al. A computational genomics pipeline for microbial sequencing projects. Bioinformatics. 2010;26:1819-26.
• Katz LS, Bolen CR, Harcourt BH, et al. Meningococcus genome informatics platform: a system for analyzing multilocus sequence typing data. Nucleic Acids Res, 2009;37:606-11.
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the Factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379-89.
• Whitney AM, Coulson GB, von Gottberg A, et al. Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol. 2009;47:2787-93.
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-107.
• Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. J Clin Microbiol. 2005;24:4811-4.
• Mothershed EA, Sacchi CT, Whitney AM, et al. Use of Real-Time PCR To Resolve Slide Agglutination Discrepancies in Serogroup Identification of Neisseria meningitidis. J Clin Microbiol. 2004;42(1):320-28.

Top of Page